Immune cells in the retina can spontaneously regenerate
- Details
- Written by Lesley Earl
- Category: Health News
Washington, DC - Immune cells called microglia can completely repopulate themselves in the retina after being nearly eliminated, according to a new study in mice from scientists at the National Eye Institute (NEI). The cells also re-establish their normal organization and function. The findings point to potential therapies for controlling inflammation and slowing progression of rare retinal diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), the most common cause of blindness among Americans 50 and older. A report on the study was published online today in Science Advances. The NEI is part of the National Institutes of Health.
NIH scientists describe potential antibody approach for treating multidrug-resistant Klebsiella pneumoniae
- Details
- Written by Ken Pekoc
- Category: Health News
Washington, DC - Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide, allowing immune system cells called neutrophils to attack and kill the bacteria. The early stage, in vitro research was conducted by scientists at the National Institute of Allergy and Infectious Diseases’ (NIAID) Rocky Mountain Laboratories and the New Jersey Medical School-Rutgers University.
FDA updates public information about known risk of lymphoma from breast implants
- Details
- Written by IVN
- Category: Health News
Washington, DC - Today, the FDA is communicating updated information about its understanding of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
Brain Injury: Know the Signs
- Details
- Written by Yan Kennon
- Category: Health News
Jacksonville, Florida - National Brain Injury Awareness Month is a time to recognize the millions of Americans living with traumatic brain injury (TBI)-related disabilities.
FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy
- Details
- Written by IVN
- Category: Health News
Washington, DC - The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
FDA approves new HIV treatment for patients who have limited treatment options
- Details
- Written by Theresa Eisenman
- Category: Health News
Washington, DC - The U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.
Page 2937 of 3785